The abstract is read at the publisher; the summary is JClub's.
CRMP treatment reduced early- and late-stage atheroprogression in HFCD-fed Ldlr-/- mice, lowering total plaque burden and lesion size while increasing plaque stability.
- Why it matters: ASCVD remains a major problem in insulin resistance, and effective therapies that target cardiometabolic atherogenesis are still needed.
- What they did: In Ldlr-/- mice on a high-fat cholesterol diet, CRMP was given and aortic root morphometry, plasma/hepatic triglycerides, insulin sensitivity by hyperinsulinemic-euglycemic clamps, and lesional inflammasome/IL-1β readouts were measured.
- The result: CRMP decreased neutral lipid and lesional macrophage content and limited inflammasome activation and IL-1β release, linked to mild macrophage mitochondrial inefficiency and lower mitochondrial ROS, but it failed in chow-fed Apoe-/- mice.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.